Neuraminidase Inhibitor Susceptibility Network position statement : antiviral resistance in influenza A/H5N1 viruses
The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availabi...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2005-01, Vol.10 (8), p.873-877 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 877 |
|---|---|
| container_issue | 8 |
| container_start_page | 873 |
| container_title | Antiviral therapy |
| container_volume | 10 |
| creator | HAYDEN, Frederick KLIMOV, Alexander ZAMBON, Maria TASHIRO, Masato HAY, Alan MONTO, Arnold MCKIMM-BRESCHKIN, Jennifer MACKEN, Catherine HAMPSON, Alan WEBSTER, Robert G AMYARD, Michele |
| description | The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner. |
| doi_str_mv | 10.1177/135965350501000811 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69085739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69085739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-9d58466d9d266a1943a4387a3ed390b7eb5ca680045b6a6b71ea6e827be2de6e3</originalsourceid><addsrcrecordid>eNplkE1LHEEQhpuQoBvjH8hB-hJvE6unp7-8iZgoyHpIPA81M7Wk40zP2t2j6K9PLy54CBQURT1vQT2MfRXwXQhjzoRUTiupQIEAACvEB7aqoYGqBmU_stUOqHbEIfuc0l-A2jqAA3YodCNBuHrF8pqWiJMPfsBE_Cb88Z3Pc-S_ltTTNpdp9PmFryk_z_GBb-fks58DTxkzTRQyP-cYsn_yEUceKfmyCT1xH0ptxoXCK_KLs2u1FrxAS6L0hX3a4JjoeN-P2P2Pq9-X19Xt3c-by4vbqpdG5coNyjZaD26otUbhGomNtAYlDdJBZ6hTPWoL0KhOo-6MINRka9NRPZAmecRO3-5u4_y4UMrt5MtX44iB5iW12oFVRroC1m9gH-eUIm3abfQTxpdWQLtz3f7vuoRO9teXbqLhPbKXW4BvewBTj-MmFi8-vXOmAWGskP8ABgGH-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69085739</pqid></control><display><type>article</type><title>Neuraminidase Inhibitor Susceptibility Network position statement : antiviral resistance in influenza A/H5N1 viruses</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>HAYDEN, Frederick ; KLIMOV, Alexander ; ZAMBON, Maria ; TASHIRO, Masato ; HAY, Alan ; MONTO, Arnold ; MCKIMM-BRESCHKIN, Jennifer ; MACKEN, Catherine ; HAMPSON, Alan ; WEBSTER, Robert G ; AMYARD, Michele</creator><creatorcontrib>HAYDEN, Frederick ; KLIMOV, Alexander ; ZAMBON, Maria ; TASHIRO, Masato ; HAY, Alan ; MONTO, Arnold ; MCKIMM-BRESCHKIN, Jennifer ; MACKEN, Catherine ; HAMPSON, Alan ; WEBSTER, Robert G ; AMYARD, Michele</creatorcontrib><description>The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.1177/135965350501000811</identifier><identifier>PMID: 16430192</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Acetamides - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Computer Communication Networks ; Drug Resistance, Viral ; Enzyme Inhibitors - pharmacology ; Enzyme Inhibitors - therapeutic use ; Guanidines - pharmacology ; Humans ; Influenza A Virus, H5N1 Subtype - drug effects ; Influenza, Human - drug therapy ; Medical sciences ; Neuraminidase - antagonists & inhibitors ; Oseltamivir ; Pharmacology. Drug treatments ; Pyrans - pharmacology ; Sialic Acids - pharmacology ; Viral Matrix Proteins - antagonists & inhibitors ; Zanamivir</subject><ispartof>Antiviral therapy, 2005-01, Vol.10 (8), p.873-877</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-9d58466d9d266a1943a4387a3ed390b7eb5ca680045b6a6b71ea6e827be2de6e3</citedby><cites>FETCH-LOGICAL-c375t-9d58466d9d266a1943a4387a3ed390b7eb5ca680045b6a6b71ea6e827be2de6e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17401781$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16430192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HAYDEN, Frederick</creatorcontrib><creatorcontrib>KLIMOV, Alexander</creatorcontrib><creatorcontrib>ZAMBON, Maria</creatorcontrib><creatorcontrib>TASHIRO, Masato</creatorcontrib><creatorcontrib>HAY, Alan</creatorcontrib><creatorcontrib>MONTO, Arnold</creatorcontrib><creatorcontrib>MCKIMM-BRESCHKIN, Jennifer</creatorcontrib><creatorcontrib>MACKEN, Catherine</creatorcontrib><creatorcontrib>HAMPSON, Alan</creatorcontrib><creatorcontrib>WEBSTER, Robert G</creatorcontrib><creatorcontrib>AMYARD, Michele</creatorcontrib><title>Neuraminidase Inhibitor Susceptibility Network position statement : antiviral resistance in influenza A/H5N1 viruses</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.</description><subject>Acetamides - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Computer Communication Networks</subject><subject>Drug Resistance, Viral</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Guanidines - pharmacology</subject><subject>Humans</subject><subject>Influenza A Virus, H5N1 Subtype - drug effects</subject><subject>Influenza, Human - drug therapy</subject><subject>Medical sciences</subject><subject>Neuraminidase - antagonists & inhibitors</subject><subject>Oseltamivir</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyrans - pharmacology</subject><subject>Sialic Acids - pharmacology</subject><subject>Viral Matrix Proteins - antagonists & inhibitors</subject><subject>Zanamivir</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkE1LHEEQhpuQoBvjH8hB-hJvE6unp7-8iZgoyHpIPA81M7Wk40zP2t2j6K9PLy54CBQURT1vQT2MfRXwXQhjzoRUTiupQIEAACvEB7aqoYGqBmU_stUOqHbEIfuc0l-A2jqAA3YodCNBuHrF8pqWiJMPfsBE_Cb88Z3Pc-S_ltTTNpdp9PmFryk_z_GBb-fks58DTxkzTRQyP-cYsn_yEUceKfmyCT1xH0ptxoXCK_KLs2u1FrxAS6L0hX3a4JjoeN-P2P2Pq9-X19Xt3c-by4vbqpdG5coNyjZaD26otUbhGomNtAYlDdJBZ6hTPWoL0KhOo-6MINRka9NRPZAmecRO3-5u4_y4UMrt5MtX44iB5iW12oFVRroC1m9gH-eUIm3abfQTxpdWQLtz3f7vuoRO9teXbqLhPbKXW4BvewBTj-MmFi8-vXOmAWGskP8ABgGH-w</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>HAYDEN, Frederick</creator><creator>KLIMOV, Alexander</creator><creator>ZAMBON, Maria</creator><creator>TASHIRO, Masato</creator><creator>HAY, Alan</creator><creator>MONTO, Arnold</creator><creator>MCKIMM-BRESCHKIN, Jennifer</creator><creator>MACKEN, Catherine</creator><creator>HAMPSON, Alan</creator><creator>WEBSTER, Robert G</creator><creator>AMYARD, Michele</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Neuraminidase Inhibitor Susceptibility Network position statement : antiviral resistance in influenza A/H5N1 viruses</title><author>HAYDEN, Frederick ; KLIMOV, Alexander ; ZAMBON, Maria ; TASHIRO, Masato ; HAY, Alan ; MONTO, Arnold ; MCKIMM-BRESCHKIN, Jennifer ; MACKEN, Catherine ; HAMPSON, Alan ; WEBSTER, Robert G ; AMYARD, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-9d58466d9d266a1943a4387a3ed390b7eb5ca680045b6a6b71ea6e827be2de6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Acetamides - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Computer Communication Networks</topic><topic>Drug Resistance, Viral</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Guanidines - pharmacology</topic><topic>Humans</topic><topic>Influenza A Virus, H5N1 Subtype - drug effects</topic><topic>Influenza, Human - drug therapy</topic><topic>Medical sciences</topic><topic>Neuraminidase - antagonists & inhibitors</topic><topic>Oseltamivir</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyrans - pharmacology</topic><topic>Sialic Acids - pharmacology</topic><topic>Viral Matrix Proteins - antagonists & inhibitors</topic><topic>Zanamivir</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAYDEN, Frederick</creatorcontrib><creatorcontrib>KLIMOV, Alexander</creatorcontrib><creatorcontrib>ZAMBON, Maria</creatorcontrib><creatorcontrib>TASHIRO, Masato</creatorcontrib><creatorcontrib>HAY, Alan</creatorcontrib><creatorcontrib>MONTO, Arnold</creatorcontrib><creatorcontrib>MCKIMM-BRESCHKIN, Jennifer</creatorcontrib><creatorcontrib>MACKEN, Catherine</creatorcontrib><creatorcontrib>HAMPSON, Alan</creatorcontrib><creatorcontrib>WEBSTER, Robert G</creatorcontrib><creatorcontrib>AMYARD, Michele</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAYDEN, Frederick</au><au>KLIMOV, Alexander</au><au>ZAMBON, Maria</au><au>TASHIRO, Masato</au><au>HAY, Alan</au><au>MONTO, Arnold</au><au>MCKIMM-BRESCHKIN, Jennifer</au><au>MACKEN, Catherine</au><au>HAMPSON, Alan</au><au>WEBSTER, Robert G</au><au>AMYARD, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neuraminidase Inhibitor Susceptibility Network position statement : antiviral resistance in influenza A/H5N1 viruses</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>10</volume><issue>8</issue><spage>873</spage><epage>877</epage><pages>873-877</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts--members of the Neuraminidase Inhibitor Susceptibility Network--on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>16430192</pmid><doi>10.1177/135965350501000811</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2005-01, Vol.10 (8), p.873-877 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69085739 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Acetamides - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Computer Communication Networks Drug Resistance, Viral Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Guanidines - pharmacology Humans Influenza A Virus, H5N1 Subtype - drug effects Influenza, Human - drug therapy Medical sciences Neuraminidase - antagonists & inhibitors Oseltamivir Pharmacology. Drug treatments Pyrans - pharmacology Sialic Acids - pharmacology Viral Matrix Proteins - antagonists & inhibitors Zanamivir |
| title | Neuraminidase Inhibitor Susceptibility Network position statement : antiviral resistance in influenza A/H5N1 viruses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T19%3A59%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neuraminidase%20Inhibitor%20Susceptibility%20Network%20position%20statement%20:%20antiviral%20resistance%20in%20influenza%20A/H5N1%20viruses&rft.jtitle=Antiviral%20therapy&rft.au=HAYDEN,%20Frederick&rft.date=2005-01-01&rft.volume=10&rft.issue=8&rft.spage=873&rft.epage=877&rft.pages=873-877&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.1177/135965350501000811&rft_dat=%3Cproquest_cross%3E69085739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69085739&rft_id=info:pmid/16430192&rfr_iscdi=true |